DEXLEVO First in Asia to Win BEST Injectable Award at AMWC, the World's Largest Congress for Aesthetic Anti-aging
12.5.2022 05:29:00 EEST | Business Wire | Press release
The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005974/en/
The aesthetic and medical device company DEXLEVO attended the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco and explained its products to the visitors. (Photo: Business Wire)
The world's first fully liquid PCL (polycaprolactone) injectable, GOURI developed by DEXLEVO, an aesthetic and medical device company, was the first in Asia to be chosen as Best Injectable in the category at the 20th AMWC (Aesthetic & Anti-aging Medicine World Congress) held in Monaco from March 31 to April 2, 2022.
AMWC is one of the world's most prestigious aesthetic and anti-aging congresses. More than 20,000 visitors from more than 200 countries worldwide, including dermatologists, attend the event every year to share the latest trends in aesthetic and anti-aging products and industry trends.
DEXLEVO launched GOURI, the world's first fully liquid PCL injectable, at the AMWC in 2021. Attending AMWC for the second year, it won the Best Injectable award for the first time as an Asian company at the AMWC Awards, having its unique technology and products recognized on the world stage. For the AMWC Awards, the AMWC Committee reviews and chooses the candidate products, judged by votes from dermatologists and industry workers around the world. At this year's review, DEXLEVO was nominated alongside prominent global beauty companies such as Allergan, Merz, Fillmed, and Aptos, proving its competence in the global market.
More than 150 doctors and companies visited DEXLEVO's booth and showed great interest in GOURI, which provides a fundamental solution to anti-aging.
Under the theme of "1st Liquid PCL-What, When, Why?", Mexican dermatologist Dr. Arturo Vela said, "The beauty market now wants naturalness. DEXLEVO's GOURI is the world's first fully liquid PCL injectable and the safest anti-aging product that meets consumer needs." Croatian dermatologist Dr. Dinko Kaliterna gave a treatment lecture at the congress under the theme "Skin Rejuvenation with Liquid PCL," saying, "GOURI is safer than competing products and its treatment is very convenient. Also, patient’s satisfaction with the procedure is high due to the natural collagen regeneration effect."
An official from DEXLEVO said, "As the trend in the beauty market changes, more companies are showing interest compared to last year's AMWC. Since the global market is showing increasing interest in GOURI, we plan to support marketing to become a leader in anti-aging products."
DEXLEVO's GOURI is the world's first fully liquid type PCL injectable of polycaprolactone (PCL), a biodegradable polymer material, that spreads naturally throughout the face and around the eyes when injected into the skin, forming a three-dimensional matrix and causing collagen production.
With the launch of AMWC in September 2021, DEXLEVO is selling and contracting GOURI in more than 40 countries and will participate as a platinum sponsor in IMCAS 2022, to be held in Paris in June this year, to accelerate marketing activities and expand the global market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005974/en/
Contact information
DEXLEVO
Marketing Department
Chris Jeong
chrisjeong@dexlevo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom